YQYu Qian

Yu Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Qian has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine Learning Analysis of Post-Acute COVID Symptoms Identifies Distinct Clusters, Severity Groups, and Trajectories

    by Beverly Peng, Thomas Dalhuisen, Aidan Rogers, Violeta Capric, Helen E. Davies, Steven G. Deeks, Christopher L. Dupont, Jesus Estevez, Marcelo Freire, Natalie S. Haddad, et al.

    Questionnaires that capture patient-reported symptomatology provide low-cost but potentially high-value data for the de novo discovery of disease phenotype, severity, and responsiveness to intervention groupings within an umbrella condition. The availability of comprehensive electronic health records (EHRs) has nonetheless overshadowed the use of questionnaires data for symptom analysis in the context of COVID-19. We analyzed de-identified questionnaires from post-acute COVID-19 cohorts at the University of California, San Francisco (UCSF, n = 669), Icahn School of Medicine at Mount Sinai (ISMMS, n = 615), Emory University (Emory, n = 60), and the University Hospital of Wales (Cardiff, n = 317). Using topic modeling followed by unsupervised clustering, we identified distinct symptom clusters and their corresponding symptom signatures. Mapping these signatures to organ systems revealed nine to twelve endotypes per cohort, capturing the heterogeneity of post-COVID-19 symptoms. Some clusters were associated with pre-existing conditions, including a female-predominant severity cluster with neurological and hormonal symptoms. Longitudinal analysis distinguished three symptom trajectories of individual symptoms: acute then resolving, persistent but attenuated, and progressive disease. Symptom severity correlates between the acute and the long COVID phases. Individuals with non-mild symptoms in the acute phase have 2.6 times the risk of developing moderate or severe long COVID symptoms, compared with individuals with mild symptoms in the acute phase. Across all cohorts, three severity levels, namely, mild, moderate, and severe, were evident from symptoms alone. Symptom-based severity scores correlated with patient-reported health status (EQ-5D) and SARS-CoV-2-specific antibody responses in plasmablasts, validating the prediction. Cluster-level analyses further stratified patients into recovered and non-recovered subgroups, identifying endotypes associated with different recovery trajectories. Finally, meta-analysis integrating cohort-specific clusters defined ten global endotypes and a unified map of severity scores, highlighting cohort-specific patterns, sex differences, and relationships among organ systems. These findings demonstrate that machine learning-assisted screening of questionnaire data can robustly identify symptom clusters, endotypes, and severity groups, providing a framework for stratifying long COVID patients for precision medicine trial design.

  • Open Access

    BayesCurveFit: Enhancing Curve Fitting for Early-Stage Compound Screening Using Bayesian Inference

    by Niu Du, Yang Chen, Yu Qian

    Accurate curve fitting is central to quantifying dose–response relationships in drug discovery. However, commonly used regression-based methods are ill-suited for early prescreening assays, where measurements are sparse and experimental noise can dominate. Bayesian approaches have been developed previously, but they are rarely optimized for such data-limited, noise-prone conditions. We present BayesCurveFit , a Bayesian framework specifically designed for robust dose–response inference under data scarcity. The workflow integrates calibrated initialization, stochastic optimization, adaptive posterior sampling, and probabilistic mixture modeling within a unified Bayesian pipeline, enabling reliable parameter estimation and uncertainty quantification from few observations. By modeling residuals with a Gaussian–Laplace hybrid distribution, BayesCurveFit remains robust to outliers where ordinary least squares and conventional regression methods fail. Simulation studies and real screening benchmarks demonstrate that BayesCurveFit outperforms state-of-the-art regression-based methods in recovering true dose–response relationships under limited sampling. In addition, a Bayesian measure of significance – posterior error probability – offers interpretable probabilistic confidence for response classification. Together, these features establish a general and easy-to-use Bayesian framework for analyzing dose–response data in early screening experiments.

  • Open Access

    A cell-level discriminative neural network model for diagnosis of blood cancers

    by Edgar E Robles, Ye Jin, Padhraic Smyth, Richard H Scheuermann, Jack D Bui, Huan-You Wang, Jean Oak, Yu Qian

    Precise identification of cancer cells in patient samples is essential for accurate diagnosis and clinical monitoring but has been a significant challenge in machine learning approaches for cancer precision medicine. In most scenarios, training data are only available with disease annotation at the subject or sample level. Traditional approaches separate the classification process into multiple steps that are optimized independently. Recent methods either focus on predicting sample-level diagnosis without identifying individual pathologic cells or are less effective for identifying heterogeneous cancer cell phenotypes. We developed a generalized end-to-end differentiable model, the Cell Scoring Neural Network (CSNN), which takes sample-level training data and predicts the diagnosis of the testing samples and the identity of the diagnostic cells in the sample, simultaneously. The cell-level density differences between samples are linked to the sample diagnosis, which allows the probabilities of individual cells being diagnostic to be calculated using backpropagation. We applied CSNN to two independent clinical flow cytometry datasets for leukemia diagnosis. In both qualitative and quantitative assessments, CSNN outperformed preexisting neural network modeling approaches for both cancer diagnosis and cell-level classification. Post hoc decision trees and 2D dot plots were generated for interpretation of the identified cancer cells, showing that the identified cell phenotypes match the cancer endotypes observed clinically in patient cohorts. Independent data clustering analysis confirmed the identified cancer cell populations. The source code of CSNN and datasets used in the experiments are publicly available on GitHub (http://github.com/erobl/csnn). Raw FCS files can be downloaded from FlowRepository (ID: FR-FCM-Z6YK).


  • Open Access

    Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19

    by Hyesun Jang, Saibyasachi Choudhury, Yanbao Yu, Benjamin L. Sievers, Terri Gelbart, Harinder Singh, Stephen A. Rawlings, Amy Proal, Gene S. Tan, Yu Qian, et al.


  • Open Access

    A cell-level discriminative neural network model for diagnosis of blood cancers

    by Edgar E. Robles, Ye Jin, Padhraic Smyth, Richard H. Scheuermann, Jack D. Bui, Huan-You Wang, Jean Oak, Yu Qian

    Motivation: Precise identification of cancer cells in patient samples is essential for accurate diagnosis and clinical monitoring but has been a significant challenge in machine learning approaches for cancer precision medicine. In most scenarios, training data are only available with disease annotation at the subject or sample level. Traditional approaches separate the classification process into multiple steps that are optimized independently. Recent methods either focus on predicting sample-level diagnosis without identifying individual pathologic cells or are less effective for identifying heterogeneous cancer cell phenotypes. Results: We developed a generalized end-to-end differentiable model, the Cell Scoring Neural Network (CSNN), which takes the available sample-level training data and predicts both the diagnosis of the testing samples and the identity of the diagnostic cells in the sample, simultaneously. The cell-level density differences between samples are linked to the sample diagnosis, which allows the probabilities of individual cells being diagnostic to be calculated using backpropagation. We applied CSNN to two independent clinical flow cytometry datasets for leukemia diagnosis. In both qualitative and quantitative assessments, CSNN outperformed preexisting neural network modeling approaches for both cancer diagnosis and cell-level classification. Post hoc decision trees and 2D dot plots were generated for interpretation of the identified cancer cells, showing that the identified cell phenotypes match the cancer endotypes observed clinically in patient cohorts. Independent data clustering analysis confirmed the identified cancer cell populations. Availability: The source code of CSNN and datasets used in the experiments are publicly available on GitHub and FlowRepository. Contact: Edgar E. Robles: roblesee@uci.edu and Yu Qian: mqian@jcvi.org Supplementary information: Supplementary data are available on GitHub and at Bioinformatics online.


  • Open Access

    FastMix: a versatile data integration pipeline for cell type-specific biomarker inference

    by Yun Zhang, Hao Sun, Aishwarya Mandava, Brian D Aevermann, Tobias R Kollmann, Richard H Scheuermann, Xing Qiu, Yu Qian

    Flow cytometry (FCM) and transcription profiling are the two widely used assays in translational immunology research. However, there is no data integration pipeline for analyzing these two types of assays together with experiment variables for biomarker inference. Current FCM data analysis mainly relies on subjective manual gating analysis, which is difficult to be directly integrated with other automated computational methods. Existing deconvolutional analysis of bulk transcriptomics relies on predefined marker genes in the transcriptomics data, which are unavailable for novel cell types and does not utilize the FCM data that provide canonical phenotypic definitions of the cell types. We developed a novel analytics pipeline—FastMix—for computational immunology, which integrates flow cytometry, bulk transcriptomics and clinical covariates for identifying cell type-specific gene expression signatures and biomarker genes. FastMix addresses the ‘large p⁠, small n’ problem in the gene expression and flow cytometry integration analysis via a linear mixed effects model (LMER) for both cross-sectional and longitudinal studies. Its novel moment-based estimator not only reduces bias in parameter estimation but also is more efficient than iterative optimization. The FastMix pipeline also includes a cutting-edge flow cytometry data analysis method—DAFi—for identifying cell populations of interest and their characteristics. Simulation studies showed that FastMix produced smaller type I/II errors than competing methods. Validation using real data of two vaccine studies showed that FastMix identified a consistent set of signature genes as in independent single-cell RNA-seq analysis, producing additional interesting findings. Source code of FastMix is publicly available at https://github.com/terrysun0302/FastMix. Supplementary data are available at Bioinformatics online.


  • Open Access

    FastMix: A Versatile Multi-Omics Data Integration Pipeline for Cell Type-Specific Biomarker Inference

    by Yun Zhang, Hao Sun, Aishwarya Mandava, Brian D. Aevermann, Tobias R. Kollmann, Richard H. Scheuermann, Xing Qiu, Yu Qian

    We developed a novel analytic pipeline - FastMix - to integrate flow cytometry, bulk transcriptomics, and clinical covariates for statistical inference of cell type-specific gene expression signatures. FastMix addresses the “large p , small n ” problem via a carefully designed linear mixed effects model (LMER), which is applicable for both cross-sectional and longitudinal studies. With a novel moment-based estimator, FastMix runs and converges much faster than competing methods for big data analytics. The pipeline also includes a cutting-edge flow cytometry data analysis method for identifying cell population proportions. Simulation studies showed that FastMix produced smaller type I/II errors with more accurate parameter estimation than competing methods. When applied to real transcriptomics and flow cytometry data in two vaccine studies, FastMix -identified cell type-specific signatures were largely consistent with those obtained from the single cell RNA-seq data, with some unique interesting findings.

  • Open Access

    A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy

    by Ricardo da Silva Antunes, Ferran Soldevila, Mikhail Pomaznoy, Mariana Babor, Jason Bennett, Yuan Tian, Natalie Khalil, Yu Qian, Aishwarya Mandava, Richard H. Scheuermann, et al.

    The increased incidence of whooping cough worldwide suggests that current vaccination against Bordetella pertussis infection has limitations in quality and duration of protection. The resurgence of infection has been linked to the introduction of acellular vaccines (aP), which have an improved safety profile compared with the previously used whole-cell (wP) vaccines. To determine immunological differences between aP and wP priming in infancy, we performed a systems approach of the immune response to booster vaccination. Transcriptomic, proteomic, cytometric, and serologic profiling revealed multiple shared immune responses with different kinetics across cohorts, including an increase of blood monocyte frequencies and strong antigen-specific IgG responses. Additionally, we found a prominent subset of aP-primed individuals (30%) with a strong differential signature, including higher levels of expression for CCL3 , NFKBIA , and ICAM1 . Contrary to the wP individuals, this subset displayed increased PT-specific IgE responses after boost and higher antigen-specific IgG4 and IgG3 antibodies against FHA and FIM2/3 at baseline and after boost. Overall, the results show that, while broad immune response patterns to Tdap boost overlap between aP- and wP-primed individuals, a subset of aP-primed individuals present a divergent response. These findings provide candidate targets to study the causes and correlates of waning immunity after aP vaccination.


  • Differential transcriptome and development of human peripheral plasma cell subsets

    by Swetha Garimalla, Doan C. Nguyen, Jessica L. Halliley, Christopher Tipton, Alexander F. Rosenberg, Christopher F. Fucile, Celia L. Saney, Shuya Kyu, Denise Kaminski, Yu Qian, et al.

    Human antibody-secreting cells (ASCs) triggered by immunization are globally recognized as CD19 lo CD38 hi CD27 hi . Yet, different vaccines give rise to antibody responses of different longevity, suggesting ASC populations are heterogeneous. We define circulating-ASC heterogeneity in vaccine responses using multicolor flow cytometry, morphology, V H repertoire, and RNA transcriptome analysis. We also tested differential survival using a human cell-free system that mimics the bone marrow (BM) microniche. In peripheral blood, we identified 3 CD19 + and 2 CD19 – ASC subsets. All subsets contributed to the vaccine-specific responses and were characterized by in vivo proliferation and activation. The V H repertoire demonstrated strong oligoclonality with extensive interconnectivity among the 5 subsets and switched memory B cells. Transcriptome analysis showed separation of CD19 + and CD19 – subsets that included pathways such as cell cycle, hypoxia, TNF-α, and unfolded protein response. They also demonstrated similar long-term in vitro survival after 48 days. In summary, vaccine-induced ASCs with different surface markers (CD19 and CD138) are derived from shared proliferative precursors yet express distinctive transcriptomes. Equal survival indicates that all ASC compartments are endowed with long-lived potential. Accordingly, in vivo survival of peripheral long-lived plasma cells may be determined in part by their homing and residence in the BM microniche.


  • Open Access

    Bayesian Trees for Automated Cytometry Data Analysis

    by Disi Ji, Eric Nalisnick, Yu Qian, Richard H. Scheuermann, Padhraic Smyth

    Cytometry is an important single cell analysis technology in furthering our understanding of cellular biological processes and in supporting clinical diagnoses across a variety hematological and immunological conditions. Current data analysis workflows for cytometry data rely on a manual process called gating to classify cells into canonical types. This dependence on human annotation significantly limits the rate, reproducibility, and scope of cytometry’s use in both biological research and clinical practice. We develop a novel Bayesian approach for automated gating that classifies cells into different types by combining cell-level marker measurements with an informative prior. The Bayesian approach allows for the incorporation of biologically-meaningful prior information that captures the domain expertise of human experts. The inference algorithm results in a hierarchically-structured classification of individual cells in a manner that mimics the tree-structured recursive process of manual gating, making the results readily interpretable. The approach can be extended in a natural fashion to handle data from multiple different samples by the incorporation of random effects in the Bayesian model. The proposed approach is evaluated using mass cytometry data, on the problems of unsupervised cell classification and supervised clinical diagnosis, illustrating the benefits of both incorporating prior knowledge and sharing information across multiple samples.